SCHEMBL491018

SCHEMBL491018

Cc1cc(OCC[C@H](NC(=O)OC(C)(C)C)C(=O)OC2CCCC2)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 6/20 0.42
AAK1 Q2M2I8 2/20 0.38
KLK7 P49862 4/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HRH2 P25021 2/20 0.34
HRH1 P35367 2/20 0.34
GPR119 Q8TDV5 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
KLK5 Q9Y337 3/20 0.34
USP30 Q70CQ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490601 0.91 CACNA1B (0.43) CACNA1BAAK1KLK7KDM4EALDH1A1
SCHEMBL490782 0.88 AAK1 (0.50) CACNA1BAAK1KLK7HRH2HRH1
SCHEMBL490591 0.88 AAK1 (0.50) CACNA1BAAK1KLK7HRH2HRH1
SCHEMBL1147671 0.86 CACNA1B (0.47) CACNA1BAAK1KLK7ITGB3ITGA2B
SCHEMBL490851 0.84 AAK1 (0.46) CACNA1BAAK1KLK7KDM4EALDH1A1
SCHEMBL490630 0.83 AAK1 (0.49) CACNA1BAAK1KLK7HRH2HRH1
SCHEMBL490706 0.83 AAK1 (0.49) CACNA1BAAK1KLK7HRH2HRH1
SCHEMBL490686 0.80 AAK1 (0.55) CACNA1BAAK1KLK7KDM4EALDH1A1
SCHEMBL13421977 0.78 CACNA1B (0.49) CACNA1BKLK7ALDH1A1HRH2HRH1
SCHEMBL8257659 0.78 CACNA1B (0.51) CACNA1BAAK1KLK7HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106091-B2 Inhibitors of IKK-beta serine-threonine protein kinase CHROMA THERAPEUTICS LTD. (GB) 2012-01-31 US disclosed
US-8106091-B2 Inhibitors of IKK-beta serine-threonine protein kinase CHROMA THERAPEUTICS LTD. (GB) 2012-01-31 US disclosed
US-8106091-B2 Inhibitors of IKK-beta serine-threonine protein kinase CHROMA THERAPEUTICS LTD. (GB) 2012-01-31 US disclosed
EP-2086956-B1 INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE CHROMA THERAPEUTICS LTD (GB) 2011-09-14 EP disclosed
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase CHROMA THERAPEUTICS LTD. (GB) 2010-03-18 US disclosed
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase CHROMA THERAPEUTICS LTD. (GB) 2010-03-18 US disclosed
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase CHROMA THERAPEUTICS LTD. (GB) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase IKBKB, IKBKE, CHUK CACNA1B 2344/4885AAK1 1469/4885KLK7 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.